Literature DB >> 15138588

Identification of novel human neuronal leucine-rich repeat (hNLRR) family genes and inverse association of expression of Nbla10449/hNLRR-1 and Nbla10677/hNLRR-3 with the prognosis of primary neuroblastomas.

Shiho Hamano1, Miki Ohira, Eriko Isogai, Kounosuke Nakada, Akira Nakagawara.   

Abstract

To search for novel prognostic indicators, we previously cloned >2,000 novel genes from primary neuroblastoma (NBL) cDNA libraries and screened for differential expression between the subsets with favorable (stage 1 or 2 with a single copy of MYCN) and unfavorable (stage 3 or 4 with amplification of MYCN) prognosis. From them, we have identified 3 genes of human neuronal leucine-rich repeat protein (NLRR) family: Nbla10449/hNLRR-1, Nbla00061/hNLRR-2/GAC1 and Nbla10677/hNLRR-3. An additional family member, hNLRR-5, was also found by homology search against public database. NLRR family proteins have been proposed to function as a neuronal adhesion molecule or soluble ligand binding receptor like Drosophila toll and slit with multiple domains including 11 sets of extracellular leucine-rich repeat (LRR)-motifs. However, the functional role of the NLRR protein family has been elusive. Our present study shows that hNLRR mRNAs are preferentially expressed in nervous system and/or adrenal gland. In cancer cell lines, hNLRR-1, hNLRR-3 and hNLRR-5 are expressed at high levels in the neural crest-derived cells. Most remarkably, in primary NBLs, hNLRR-1 is significantly expressed at high levels in unfavorable subsets as compared to favorable ones, whereas the expression pattern of hNLRR-3 and hNLRR-5 is the opposite. In order to understand the function of these receptors, we have used newborn mouse superior cervical ganglion (SCG) cells which are dependent on nerve growth factor (NGF) for their survival. Expression of the mouse counterparts of hNLRR-2 and hNLRR-3 is up-regulated after NGF-induced differentiation and down-regulated after NGF depletion-induced apoptosis. On the other hand, expression of hNLRR-1 and hNLRR-5 is inversely regulated in the same system. These results have suggested that the regulation of the hNLRR family genes may be associated with NGF signaling pathway in both SCG cells and neuroblastoma. Our quantitative real-time RT-PCR analysis using 99 primary NBLs has revealed that high levels of hNLRR-1 expression are significantly associated with older age (>1 year, p=0.0001), advanced stages (p=0.0007), low expression of TrkA (p=0.011), and MYCN amplification (p=0.0001), while those of hNLRR-3 expression are significantly correlated with the favorable prognostic indicators. Furthermore, multivariate analysis reveals that expression of hNLRR-1 is an independent prognostic indicator in human neuroblastoma. Thus, our results demonstrate that, despite being members of the same family, hNLRR-1 and hNLRR-3 may share different biological function among the NBL subsets, and that their expression level becomes novel prognostic indicators of NBL.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15138588

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  12 in total

1.  LRRC4 controls in vitro invasion of glioblastoma cells through inhibiting RPTP-zeta expression.

Authors:  Minghua Wu; Kai Gan; Chen Huang; Yunlian Tang; Qiong Chen; Ke Tang; Xiaoling Li; Shourong Shen; Guiyuan Li
Journal:  J Neurooncol       Date:  2006-08-29       Impact factor: 4.130

2.  Large fragment Bst DNA polymerase for whole genome amplification of DNA from formalin-fixed paraffin-embedded tissues.

Authors:  Sarit Aviel-Ronen; Chang Qi Zhu; Bradley P Coe; Ni Liu; Spencer K Watson; Wan L Lam; Ming Sound Tsao
Journal:  BMC Genomics       Date:  2006-12-12       Impact factor: 3.969

3.  Long non-coding RNA LINC00628 functions as a gastric cancer suppressor via long-range modulating the expression of cell cycle related genes.

Authors:  Zi-Zhen Zhang; Gang Zhao; Chun Zhuang; Yan-Ying Shen; Wen-Yi Zhao; Jia Xu; Ming Wang; Chao-Jie Wang; Lin Tu; Hui Cao; Zhi-Gang Zhang
Journal:  Sci Rep       Date:  2016-06-08       Impact factor: 4.379

4.  Unfavorable neuroblastoma prognostic factor NLRR2 inhibits cell differentiation by transcriptional induction through JNK pathway.

Authors:  Afzal Sheikh; Atsushi Takatori; Md Shamim Hossain; Md Kamrul Hasan; Masatoshi Tagawa; Hiroki Nagase; Akira Nakagawara
Journal:  Cancer Sci       Date:  2016-09-02       Impact factor: 6.716

5.  Neuronal leucine-rich repeat 1 negatively regulates anaplastic lymphoma kinase in neuroblastoma.

Authors:  Shunpei Satoh; Atsushi Takatori; Atsushi Ogura; Kenichi Kohashi; Ryota Souzaki; Yoshiaki Kinoshita; Tomoaki Taguchi; Md Shamim Hossain; Miki Ohira; Yohko Nakamura; Akira Nakagawara
Journal:  Sci Rep       Date:  2016-09-08       Impact factor: 4.379

6.  Evaluation of a biomarker for the diagnosis of pancreas cancer using an animal model.

Authors:  Katsumi Fukamachi; Yoshiaki Hagiwara; Mitsuru Futakuchi; David B Alexander; Hiroyuki Tsuda; Masumi Suzui
Journal:  J Toxicol Pathol       Date:  2019-04-04       Impact factor: 1.628

7.  NLRR1 Is a Potential Therapeutic Target in Neuroblastoma and MYCN-Driven Malignant Cancers.

Authors:  Atsushi Takatori; Md Shamim Hossain; Atsushi Ogura; Jesmin Akter; Yohko Nakamura; Akira Nakagawara
Journal:  Front Oncol       Date:  2021-06-25       Impact factor: 6.244

8.  Analysis of Lrrn1 expression and its relationship to neuromeric boundaries during chick neural development.

Authors:  Laura C Andreae; Daniela Peukert; Andrew Lumsden; Jonathan D Gilthorpe
Journal:  Neural Dev       Date:  2007-10-31       Impact factor: 3.842

9.  Apoptotic cell death in neuroblastoma.

Authors:  Yuanyuan Li; Akira Nakagawara
Journal:  Cells       Date:  2013-06-20       Impact factor: 6.600

10.  Identification of time‑series differentially expressed genes and pathways associated with heart failure post‑myocardial infarction using integrated bioinformatics analysis.

Authors:  Xuefei Li; Bin Li; Hong Jiang
Journal:  Mol Med Rep       Date:  2019-04-24       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.